Cemiplimab for advanced lung cancer with high PD-L1
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV or stage IIIB/C non-small cell lung cancer that cannot be treated with surgery or standard chemo-radiation.
- Your tumor has a high level of PD-L1 (at least 50%).
- You have not had any prior chemotherapy or radiation for advanced lung cancer.
- You are in good physical condition (able to care for yourself and be up and about more than half of waking hours).
- You do not have certain gene changes (EGFR, ALK, ROS1) that can be treated with targeted pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of treatments (an immunotherapy drug called cemiplimab plus chemotherapy) for people with advanced lung cancer that has not been treated yet and shows a high PD-L1 level. The study also looks at a specific blood marker to see if it predicts how the cancer responds, aiming to avoid rapid growth (hyperprogression).
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This trial tests a new way of giving chemotherapy and an immunotherapy drug (cemiplimab) before surgery for lung cancer that has a high PD-L1 level. The goal is to see if a shorter or adjusted course can shrink the tumor and improve outcomes while reducing side effects.
This observational study looks at how well cemiplimab works and how safe it is for adults with advanced non-small cell lung cancer in everyday care in Europe. It mainly follows patients already prescribed cemiplimab, and asks them to complete questionnaires.
This study tests a new immunotherapy drug (cemiplimab) combined with chemotherapy for advanced squamous lung cancer. The treatment is chosen based on a blood test that measures a natural body enzyme, which may help predict how well the chemotherapy works.
This trial tests whether giving the drug cemiplimab before surgery can help treat early-stage non-small cell lung cancer. The goal is to see if it shrinks the tumor or improves outcomes when followed by standard surgery.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.